Related Experiment Videos
Prednisolone plus albuterol versus albuterol alone in mild to moderate bronchiolitis
J Goebel1, B Estrada, J Quinonez
1Department of Pediatrics, University of South Alabama, Mobile, USA.
Insights
Combination therapy for infant bronchiolitis using albuterol and prednisolone showed transient improvement in symptoms. This bronchodilator-corticosteroid treatment may offer short-term benefits for young children with wheezing.
Area of Science:
- Pediatrics
- Pulmonology
- Pharmacology
Background:
- Bronchiolosis is a common viral respiratory infection in infants.
- Wheezing and respiratory tract infections are hallmark symptoms.
- Current treatment often involves supportive care, with limited evidence for combination therapies.
Purpose of the Study:
- To evaluate the efficacy of combining albuterol (a bronchodilator) with prednisolone (a corticosteroid) for treating mild to moderate bronchiolitis.
- To assess the impact of this combination therapy on disease severity in young children.
Main Methods:
- A randomized controlled trial involving 51 young children with first-time wheezing and respiratory symptoms.
- Participants received either albuterol plus prednisolone or albuterol plus placebo for 5 days.
- Disease severity was systematically scored on days 0, 2, 3, and 6.
Main Results:
- On day 2, the albuterol-prednisolone group exhibited significantly lower disease severity scores compared to the placebo group (p < 0.05).
- No significant difference in disease severity was observed between the groups by day 6.
- This suggests a transient, short-term acceleration of recovery.
Conclusions:
- Combination therapy with albuterol and prednisolone may offer a temporary benefit in reducing bronchiolitis severity in young children.
- The clinical significance of this transient effect requires further investigation.
- Future studies should explore long-term outcomes and optimal treatment durations.
Abstract:
To evaluate combination therapy of mild to moderate bronchiolitis with bronchiodilators and corticosteroids, we treated 51 young children with first-time wheezing and symptoms of respiratory tract infection with albuterol plus either prednisolone or placebo for 5 days. Disease severity was scored on days 0, 2, 3, and 6. On day 2, prednisolone resulted in significantly lower scores (2.7 +/- 1.4 vs. 4.0 +/- 1.5 in all patients evaluated, p < 0.05) than placebo, whereas there was no detectable difference on day 6, suggesting that addition of prednisolone to albuterol transiently accelerates recovery from bronchiolitis. The clinical significance of this effect needs to be evaluated in further studies.